Search the Newsreel

Elicio Therapeutics' (ELTX) "Buy" Rating Reaffirmed at HC Wainwright

HC Wainwright has reaffirmed its "Buy" rating for Elicio Therapeutics (ELTX), with an average analyst price target of $19.75, indicating a "Moderate Buy" consensus. Despite this, ELTX shares opened down 2.3% at $3.02, trading below key moving averages and near its 52-week low. The …

Enliven Therapeutics (NASDAQ:ELVN) Now Covered by Barclays

Barclays has initiated coverage on Enliven Therapeutics (NASDAQ:ELVN) with an "overweight" rating and a $78 price target, suggesting a potential upside of 31.03%. This comes amidst mixed analyst sentiment, with a consensus "Moderate Buy" rating and an average target price of $75. The company …

VKTX Stock Draws Fresh Attention Ahead Of Earnings: Wall Street Sees Over 170% Upside As GLP-1 Race Burns Hot

Odyssey Therapeutics Hits $900M Valuation In Nasdaq Debut, Stock Climbs 13% Before Diving Lower

Amentum Joint Venture Selected for Australia Nuclear Submarine Shipyard Program

CHANTILLY, Va., August 18, 2026--(BUSINESS WIRE)--Australian Naval Infrastructure (ANI) selected a joint venture between Amentum (NYSE: AMTM) and Laing O'Rourke as its Capability Partner to support the delivery of a nuclear-powered submarine construction yard in South Australia. Under a long-term contract, Amentum and Laing …

RNTX Reiterated by HC Wainwright & Co. -- Price Target Maintained at $8.00

HC Wainwright & Co. has reiterated its 'Buy' rating for Rein Therapeutics (RNTX), maintaining a price target of $8.00. Despite the stock trading significantly below this target at $0.849, the company faces financial weaknesses, particularly in profitability, as indicated by its GF Score™ of …

Rein Therapeutics (NASDAQ:RNTX) Given "Buy" Rating at HC Wainwright

HC Wainwright has reaffirmed its "Buy" rating for Rein Therapeutics (NASDAQ:RNTX), while the broader analyst consensus remains "Hold" with an average price target of $6.00. The clinical-stage biotechnology company is developing RT-101, an early-phase immuno-oncology therapy for solid tumors, and recently reported a quarterly …

INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces

Robbins Geller Rudman & Dowd LLP has announced a class action lawsuit against Capricor Therapeutics, Inc. (NASDAQ: CAPR) for alleged securities law violations between December 17, 2025, and July 26, 2026. Investors who suffered substantial losses during this period have until September 28, 2026, …

Pliant Therapeutics Receives FDA Fast Track Designation for PLN-101095 in Combination with Pembrolizumab for the Treatment of ICI-Refractory Solid Tumors

Pliant Therapeutics announced that the FDA has granted Fast Track designation for its drug candidate, PLN-101095, in combination with pembrolizumab. This designation is for treating solid tumors resistant to immune checkpoint inhibitors (ICIs). The Fast Track status aims to expedite the development and review …

Equities Analysts Set Expectations for PRQR FY2030 Earnings

HC Wainwright has updated its FY2030 earnings per share estimate for ProQR Therapeutics (NASDAQ:PRQR) to $0.20, an increase from $0.18, and reiterated a "Buy" rating. Despite this positive revision, the consensus full-year earnings estimate remains a loss of $0.52 per share. The biopharmaceutical company …

HC Wainwright Has Bullish Forecast for FDMT FY2027 Earnings

Tenaya Therapeutics (TNYA) Falls 3.85% to $0.70 as Shares Approach Critical Support - Synthetic Long

Definium Therapeutics (NASDAQ:DFTX) Coverage Initiated by Analysts at Bank of America

Bank of America has initiated coverage of Definium Therapeutics (NASDAQ:DFTX) with a "buy" rating and a $75 price target, indicating a potential 65.71% upside. This positive outlook aligns with other analysts, who collectively give the company an average "Buy" rating and a $63.00 price …

Q3 EPS Estimate for MiNK Therapeutics Boosted by Analyst

HC Wainwright has increased its Q3 2026 EPS estimate for MiNK Therapeutics (NASDAQ: INKT) to a loss of $0.35 per share, up from a previous estimate of $0.63, while maintaining a "Buy" rating and a $35 price target. This adjustment comes after MiNK Therapeutics …

H.C. Wainwright raises Tango Therapeutics price target to $68 By Investing.com

H.C. Wainwright has increased its price target for Tango Therapeutics Inc. (NASDAQ:TNGX) shares to $68 from $66, maintaining a Buy rating. This adjustment follows the company's Q2 2026 results, which showed a higher net loss than previously estimated, but also revealed a strong cash …

Elicio Therapeutics stock price target reiterated at $23 by H.C. Wainwright

H.C. Wainwright has reiterated a Buy rating and a $23 price target for Elicio Therapeutics (NASDAQ:ELTX) after the company reported its second-quarter 2026 results. Despite a significant stock price drop, analyst consensus remains at Strong Buy, and the company has secured $15 million in …

Jasper Therapeutics stock rating reiterated at Buy by H.C. Wainwright

Atrium Therapeutics (RNA) Inches Higher: 0.93% Gain Reinforces Support Zone - Dark Pool Sentiment

HC Wainwright Analysts Lift Earnings Estimates for GALT

Research Analysts Offer Predictions for DWTX Q3 Earnings

Why Is Ocular Therapeutix Stock Gaining Monday?

Ocular Therapeutix Inc. (NASDAQ: OCUL) stock is trading higher on Monday after its rival, EyePoint Inc. (NASDAQ: EYPT), released underwhelming Phase 3 trial data for its wet AMD treatment. EyePoint's Duravyu failed to meet its primary visual acuity endpoint, which analysts believe validates Ocular …

Truist Adjusts Price Target on Corcept Therapeutics to $164 From $50, Maintains Buy Rating

Truist has significantly raised its price target for Corcept Therapeutics (CORT) to $164 from $50, while reiterating a Buy rating on the stock. This adjustment follows several positive updates for Corcept, including strong Q2 2026 earnings, increased revenue guidance for the full year, and …

We're Hopeful That First Tracks Biotherapeutics (NASDAQ:TRAX) Will Use Its Cash Wisely

First Tracks Biotherapeutics (NASDAQ:TRAX) has a cash runway of approximately 16 months, with US$168m in cash and a cash burn of US$124m. Despite being an early-stage company with no revenue, its cash burn rate is decreasing, and its ability to raise additional funds by …

International Paper (IP) Stock Still Looks Like A Bargain On Price Hike Scrutiny

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. After a weak 1 year share price patch, International Paper still screens as attractively priced on the broader valuation checks, which raises questions …

Medicenna Therapeutics Corp MDNA Earnings Beat Estimates by 0.0%

Meeder Asset Management Inc. Invests $10.56 Million in Tapestry, Inc. $TPR

Meeder Asset Management Inc. acquired a new stake of 72,168 shares in Tapestry, Inc. (NYSE:TPR) during the second quarter, valued at approximately $10.56 million. Tapestry recently reported strong quarterly earnings, beating analyst estimates with $1.32 EPS and an 8.9% year-over-year revenue increase to $1.88 …

Knight Therapeutics Stock Gains Bullish Momentum as Strong Growth and Raised Outlook Fuel Investor Optimism

Denali Therapeutics (DNLI) Could Be 42% Undervalued Following Its Earnings Report

Denali Therapeutics (DNLI) reported Q2 2026 revenue of US$3.6 million and a net loss of US$127.55 million. While the company's shares have shown strong recent momentum, trading at US$24.40, there are conflicting views on its valuation, with one narrative suggesting it's 41.9% undervalued at …

Definium Therapeutics (DFTX) Is Down 5.6% After Positive Phase 3 GAD Data For DT120 ODT

Definium Therapeutics reported positive Phase 3 results for its DT120 ODT in generalized anxiety disorder, showing statistically significant reductions in anxiety scores and rapid symptom improvement. Despite this clinical success, the company's stock fell, likely due to ongoing financial losses and future financing needs, …

ENLIVEN THERAPEUTICS, INC. : WILLIAM BLAIR INITIATES COVERAGE WITH OUTPERFORM RATING

William Blair has initiated coverage of Enliven Therapeutics, Inc. (ELVN.O) with an Outperform rating. The report, sourced from Reuters, indicates a positive outlook from the investment firm for the pharmaceutical company.

Pallas Capital Advisors LLC Acquires Shares of 40,511 Axsome Therapeutics, Inc. $AXSM

Pallas Capital Advisors LLC has acquired 40,511 shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) for approximately $9.9 million, adding to institutional ownership which collectively stands at 81.49%. Despite Axsome missing quarterly earnings and revenue estimates, analysts maintain a "Moderate Buy" rating with a consensus price …

Shareholder Alert: Ademi LLP investigates whether Fulcrum Therapeutics, Inc. is obtaining a Fair Price for Public Shareholders

Ademi LLP is investigating Fulcrum Therapeutics (Nasdaq: FULC) regarding potential breaches of fiduciary duty related to its transaction with Slate Medicines. The investigation focuses on whether Fulcrum's public shareholders are receiving a fair price, given that they are expected to own only 5.0% of …

Pallas Capital Advisors LLC Makes New $3.31 Million Investment in Tapestry, Inc. $TPR

Pallas Capital Advisors LLC has made a new $3.31 million investment in Tapestry, Inc. (NYSE:TPR), acquiring 22,590 shares during the second quarter. Other institutional investors have also adjusted their holdings in the luxury accessories retailer. The article also details recent analyst rating changes, insider …

Sernova Biotherapeutics Stock Slides as Funding Pressure and Clinical Execution Risks Test Investor Confidence

Spyre Therapeutics (SYRE) Edges Higher at $104.60: Consolidation Builds Ahead of Resistance Test - Call Wall

CAPR Stock Alert: Capricor Therapeutics, Inc. (CAPR) Reports Q2 Earnings Amid Ongoing Securities Class Action Lawsuit - Hagens Berman

Hagens Berman is highlighting ongoing developments concerning Capricor Therapeutics, Inc. (CAPR) following its Q2 2026 earnings release, which notably omitted a management Q&A with analysts. The company is currently facing a securities fraud class action lawsuit, with a lead plaintiff deadline set for September …